Figure 1
From: Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Kaplan-Meier estimates of the cumulative incidence of non-response to treatment, up to 600 days. (A) Previous antidiabetic treatment, (B) BMI: body mass index, (C) Duration of diabetes, (D) U-CPR: 24-h urinary C-peptide excretion, (E) CPR6: stimulated C-peptide level at 6 min during glucagon stimulation, (F) Average preprandial glucose level over 2 days after the initiation of GLP-1 receptor agonist treatment, GLP-1: Glucagon-like peptide-1.